BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $747 | -19.6% | 19,801 | -3.0% | 0.58% | -12.2% |
Q2 2023 | $929 | +12.2% | 20,410 | 0.0% | 0.66% | +6.2% |
Q1 2023 | $828 | -20.4% | 20,410 | 0.0% | 0.62% | -4.6% |
Q4 2022 | $1,040 | -99.9% | 20,410 | -0.5% | 0.65% | -4.2% |
Q3 2022 | $1,104,000 | -16.4% | 20,509 | -0.3% | 0.68% | -11.6% |
Q2 2022 | $1,321,000 | -17.4% | 20,572 | -0.2% | 0.77% | +1.6% |
Q1 2022 | $1,599,000 | -9.7% | 20,622 | +0.0% | 0.76% | -4.2% |
Q4 2021 | $1,770,000 | +4.2% | 20,621 | -2.3% | 0.79% | +0.9% |
Q3 2021 | $1,698,000 | -0.4% | 21,111 | -0.3% | 0.79% | -5.4% |
Q2 2021 | $1,704,000 | -5.2% | 21,171 | -0.7% | 0.83% | -16.8% |
Q1 2021 | $1,798,000 | +5.5% | 21,316 | +0.3% | 1.00% | -3.0% |
Q4 2020 | $1,705,000 | -0.5% | 21,246 | -0.3% | 1.03% | -14.1% |
Q3 2020 | $1,714,000 | -6.9% | 21,316 | -0.3% | 1.20% | -15.0% |
Q2 2020 | $1,841,000 | +6.0% | 21,381 | 0.0% | 1.41% | +11.4% |
Q1 2020 | $1,736,000 | -2.9% | 21,381 | 0.0% | 1.27% | +7.4% |
Q4 2019 | $1,788,000 | -4.4% | 21,381 | -0.1% | 1.18% | -11.3% |
Q3 2019 | $1,871,000 | +5.2% | 21,393 | -1.5% | 1.33% | +7.3% |
Q2 2019 | $1,779,000 | -1.4% | 21,718 | -2.1% | 1.24% | -9.6% |
Q1 2019 | $1,805,000 | +22.3% | 22,193 | -1.0% | 1.37% | +3.9% |
Q4 2018 | $1,476,000 | -21.6% | 22,418 | -8.2% | 1.32% | -6.2% |
Q3 2018 | $1,883,000 | +3.6% | 24,423 | -0.8% | 1.41% | +0.1% |
Q2 2018 | $1,818,000 | +11.8% | 24,623 | -1.5% | 1.41% | +6.5% |
Q1 2018 | $1,626,000 | +0.8% | 25,007 | +0.2% | 1.32% | +3.6% |
Q4 2017 | $1,613,000 | +1.2% | 24,952 | -1.8% | 1.27% | -8.9% |
Q3 2017 | $1,594,000 | +3.6% | 25,397 | -0.0% | 1.40% | +13.9% |
Q2 2017 | $1,538,000 | +14.7% | 25,402 | -1.7% | 1.23% | +14.0% |
Q1 2017 | $1,341,000 | +16.1% | 25,852 | -0.8% | 1.08% | +5.9% |
Q4 2016 | $1,155,000 | -7.7% | 26,057 | -0.9% | 1.02% | -7.2% |
Q3 2016 | $1,251,000 | +3.5% | 26,282 | -1.7% | 1.10% | +0.5% |
Q2 2016 | $1,209,000 | +7.9% | 26,732 | -2.0% | 1.09% | +27.6% |
Q1 2016 | $1,120,000 | +7.9% | 27,267 | +0.2% | 0.86% | +5.3% |
Q4 2015 | $1,038,000 | +16.1% | 27,217 | 0.0% | 0.81% | -2.2% |
Q3 2015 | $894,000 | -54.2% | 27,217 | -2.4% | 0.83% | -53.3% |
Q2 2015 | $1,950,000 | +0.6% | 27,892 | -1.4% | 1.78% | +12.8% |
Q1 2015 | $1,938,000 | -7.2% | 28,291 | -0.7% | 1.58% | -10.4% |
Q4 2014 | $2,089,000 | -0.8% | 28,498 | -2.8% | 1.76% | -5.0% |
Q3 2014 | $2,105,000 | +0.0% | 29,324 | +0.8% | 1.85% | +1.9% |
Q2 2014 | $2,104,000 | +0.8% | 29,098 | +2.5% | 1.82% | +2.3% |
Q1 2014 | $2,088,000 | +5.7% | 28,379 | -0.1% | 1.78% | -2.1% |
Q4 2013 | $1,976,000 | – | 28,412 | – | 1.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |